Evidence map›Paper›PMID 30864060›Full record

Observational studyWorld journal of pediatrics : WJP2019

Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China.

Zheng-Kun Xia, Yuan-Fu Gao, Li-Ping Rong, Xi-Qiang Dang, Qian Shen, Xiao-Yun Jiang, Zhu-Wen Yi, Hong Xu

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in World journal of pediatrics : WJP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Zheng-Kun XiaDepartment of Pediatrics, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China. njxzk@126.com.
Yuan-Fu GaoDepartment of Pediatrics, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Li-Ping RongDepartment of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.
Xi-Qiang DangDepartment of Pediatric Nephrology, Children's Medical Center, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Qian ShenDepartment of Nephrology and Rheumatology, Children's Hospital of Fudan University, Shanghai 201102, China.
Xiao-Yun JiangDepartment of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.
Zhu-Wen YiDepartment of Pediatric Nephrology, Children's Medical Center, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Hong XuDepartment of Nephrology and Rheumatology, Children's Hospital of Fudan University, Shanghai 201102, China.
Children's Hospital of Fudan University · CNCentral South University · CNNanjing General Hospital of Nanjing Military Command · CNNanjing University · CNSecond Xiangya Hospital of Central South University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

Jiangsu Province, China CXTDA2017022
6 · The paper itself

Abstract

backgroundMizoribine (MZR) is an immunosuppressant used to treat adult nephropathy. There is little experience with the drug in treating Chinese children with frequently relapsing nephrotic syndrome (FRNS). We investigated the efficacy and safety for treating MZR with FRNS. Furthermore, the relationship between efficacy and serum concentration was investigated.

methodsA prospective multicenter observational 12-month study was performed for evaluating the usefulness of MZR with FRNS. Serum MZR concentration was measured, and the relationships between pharmacokinetic parameters (C

resultsEighty-two pediatric patients from four hospitals were treated with MZR and prednisone. MZR treatment significantly reduced the number of relapses and steroid doses. A correlation between pharmacokinetic parameters and relapses was observed, which fits well with the sigmoidal E

conclusionsMZR therapy was effective in reducing the number of relapses and steroid doses. No severe adverse reactions were observed. Therapeutically effective serum concentrations were estimated to be C

Indexed as

AdolescentChildChild, PreschoolChinaFemaleHumansImmunosuppressive AgentsMaleNephrotic SyndromeProspective StudiesRecurrenceRibonucleosidesImmunosuppressive AgentsmizoribineRibonucleosidesFrequently relapsing nephrotic syndromeMizoribinePharmacokinetic parameters

Identifiers

PMID30864060
OpenAlexW2922245777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.